HER2+ gastroesophageal adenocarcinomas: Current standards and therapeutic prospects
Type de matériel :
TexteLangue : français Détails de publication : 2022.
Ressources en ligne : Abrégé : Esogastric adenocarcinomas (EGAs) are characterized in 10–20% of cases by overexpression and/or amplification of HER2. Current standard treatment for HER2+ EGAs relies on trastuzumab (an anti-HER2 antibody) plus a doublet of chemotherapy (fluoropyrimidine + platinum salt). For more than a decade, no obvious therapeutic progress has enriched the therapeutic arsenal for these patients, whether in the first-line with other anti-HER2 agents or in the context of trastuzumab resistance. The first results of studies based on trastuzumab deruxtecan and immune checkpoint inhibitors are therefore likely to change management practices for HER2+ EGAs.
Nous n'avons pas d'exemplaire de ce document
10
Esogastric adenocarcinomas (EGAs) are characterized in 10–20% of cases by overexpression and/or amplification of HER2. Current standard treatment for HER2+ EGAs relies on trastuzumab (an anti-HER2 antibody) plus a doublet of chemotherapy (fluoropyrimidine + platinum salt). For more than a decade, no obvious therapeutic progress has enriched the therapeutic arsenal for these patients, whether in the first-line with other anti-HER2 agents or in the context of trastuzumab resistance. The first results of studies based on trastuzumab deruxtecan and immune checkpoint inhibitors are therefore likely to change management practices for HER2+ EGAs.
Réseaux sociaux